HUTCHMED Highlights Clinical Data to be Presented at the Upcoming ASCO21 Virtual Scientific Program
May 20, 2021 02:00 ET
|
HUTCHMED (China) Limited
– HUTCHMED will review these highlights as part of its company update audio call and webcast on Wednesday, May 26 at 9 a.m. EDT to discuss data disclosures, its PD-1/L1 combination study strategy and...
Save the date: HUTCHMED to Host Company Update on R&D, Commercial and ASCO Data For Analysts and Investors
May 17, 2021 02:00 ET
|
HUTCHMED (China) Limited
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 17, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) today announces that it will host a virtual investor...
HUTCHMED to Attend Upcoming Investor Conferences
May 07, 2021 07:00 ET
|
HUTCHMED (China) Limited
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 07, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) today announces that Mr Christian Hogg, Chief Executive...
Change of Company Name
May 04, 2021 03:00 ET
|
Hutchison China MediTech Limited
HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., May 04, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (Nasdaq/AIM: HCM), formerly known as Hutchison China MediTech Limited, announces that,...
HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors
May 03, 2021 07:00 ET
|
Hutchison China MediTech Limited
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 03, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) today announces that it completed the rolling...
HUTCHMED Initiates Phase II Registration Study of HMPL-689 in Patients with Follicular Lymphoma and Marginal Zone Lymphoma in China
April 29, 2021 02:00 ET
|
Hutchison China MediTech Limited
— Single-arm study in ~180 patients, with ORR as primary endpoint — — Relapsed/refractory FL and MZL constitute approximately 25% of all NHL — — HMPL-689 trials are also underway in these and...
HUTCHMED Announces US$100 Million Equity Investment by Baring Private Equity Asia
April 08, 2021 03:30 ET
|
Hutchison China MediTech Limited
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION HONG...
HUTCHMED Initiates International Phase I Trials of IDH1/2 Dual Inhibitor in Patients with Advanced Solid Tumors or Hematological Malignancies
March 29, 2021 02:00 ET
|
Hutchison China MediTech Limited
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 29, 2021 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) has initiated two international Phase I...
HUTCHMED Enters Agreement to Divest Non-Core OTC Joint Venture for US$169 Million
March 24, 2021 09:30 ET
|
Hutchison China MediTech Limited
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 24, 2021 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) today announces that it has reached an...
HUTCHMED Initiates a Phase Ib/II Trial of Surufatinib in Combination with Tislelizumab in Patients with Advanced Solid Tumors
March 24, 2021 03:00 ET
|
Hutchison China MediTech Limited
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 24, 2021 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) has initiated a Phase Ib/II study of surufatinib in...